Exponential advances in the ability to read, write, and manipulate DNA, together with high throughput automation and ML/AI, are transforming biology from a science to a true engineering discipline. We can now measure biological systems with greater precision, model them with greater efficacy, and make targeted interventions in a patient’s health with greater probability of success.
Our primary investment scope includes pre-seed and seed-stage biotechnology companies developing platforms and products across therapeutics, diagnostics, and life sciences tools, software, and services. We have been partnering with biotech founders since our very first fund, and our biotech portfolio now includes two public companies.How we invest How we help founders
Here are some of the things we’re interested in, but there are far more than what we’ve shared on this page. If you’re building something cool, we want to hear from you, regardless of whether it’s listed here or not.
Note: we generally do not invest in medical device or medical hardware companies.
Novel therapeutic discovery platforms
We are interested in novel therapeutic discovery platforms that leverage omics-based measurement technologies such as single-cell sequencing, spatial transcriptomics, and proteomics, or that rely on manipulation techniques with a high degree of plexity or parallelization. Especially when the resulting large data sets can be analyzed with powerful computational and ML-based approaches, these technologies hold the potential to unveil previously hidden insights into the cellular and molecular basis of disease.
Next-generation therapeutic modalities
Emerging therapeutic modalities, such as genomic medicines (including gene therapy, RNA therapeutics, and gene editing), cell therapies, targeted protein degraders, and antibody-drug conjugates, have enabled more precise and effective treatments for a range of diseases and have expanded the universe of druggable targets. We are interested in technologies that can dramatically improve the efficacy, safety, and reach of these modalities.
The use of biomarkers for patient selection has significantly bolstered the likelihood of successful translation for drug programs in oncology and have enabled therapeutic product profiles with better efficacy and safety. We are excited about the broader integration of biomarker-guided drug development strategies, not only within oncology but also across diverse therapeutic areas.
Software platforms for biopharma
We anticipate software platforms will play an increasingly pivotal role across all parts of the drug development value chain, including drug discovery, clinical development, manufacturing, and sales and marketing.
Pear is always there when we need help or advice, one of our strongest champions, bringing important investors and partners to us.
Pear supported us as we grew our technology and our team, treating us like family each step of the way.
Co-Founder & CEO, Clear Labs
Biotech Executive, Board member at Omeat
Co-Founder and CEO of Guardant Health (Pear Company)
CEO and Co-Founder of BioAge (Pear Company)
Associate Professor, Department of Biophysics & Biochemistry, UCSF
President & COO, Kriya Therapeutics
Fmr. CEO of Ortho Clinical Diagnostics, Fmr. CEO of Millipore
Seasoned BioPharma BD Leader
CBO, Arrakis Therapeutics
Fmr. SVP of Pharmaceutical and Biologics Operations at Gilead
Fmr. Co-Founder and CEO, SQZ Biotech
CBO, Revolution Medicines
Founder, 5 Prime Life Science Consulting, Inc.
Assistant Professor of Biomedical Data Science, Stanford